
SMS Pharmaceuticals Q2 FY23 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
No
Order
N/A
Capex
No
0 of 4 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- FY '23 revenue growth target is around 10%; FY '24 projected growth is 15% to 20%.
- Volume growth is expected to be strong, with sequential and year-over-year volume growth seen; e.g., 30%-35% volume growth reported despite price corrections.
- Focus on ramping up ibuprofen capacity to reach INR 600-700 crores topline, becoming one of the largest manufacturers.
- Efforts to fill existing large capacity (e.g., 2,000 KL in Vizag plant) with high volume products and some niche products.
- New product launches and geographic expansion planned; anti-diabetic segment expected to contribute around 25%-30% of topline in future.
- Growth driven by higher volumes, operating leverage, and process improvements to improve margins alongside revenue increase.
- Inventory destocking expected to gradually ease over 2-3 quarters, aiding smoother sales growth.
See what SMS Pharmaceuticals management said on margin guidance — free account, 30 seconds.
Fundraise plans
No- No significant capital expenditure (capex) or expansion planned for the next one year, indicating no major immediate need for fundraising.
- The company plans only small capex related to environmental initiatives (e.g., multi-effect evaporation operator).
- Current focus is on consolidating and filling existing capacity rather than building new capacity.
- Long-term debt is INR 170 crores and short-term debt is INR 90 crores, with an average borrowing cost below 8%.
- No explicit mention of any ongoing or planned fundraising through debt or equity in the call transcript.
- Emphasis is on growing revenue via existing capacities and product mix rather than through additional funding.
See what SMS Pharmaceuticals management said on order book — free account, 30 seconds.
Capex plans
No- No significant capex planned for the next one year as the company aims to consolidate its existing capacities.
- Small capex planned is related to environmental upgrades, such as installing multi-effect evaporators (ME) and other environmental compliance equipment.
- Focus is on utilizing existing capacity (about 2,000 KL at Vizag plant for Ibuprofen) by filling it with more products rather than expanding physical capacity.
- Strategic focus is on product mix expansion, backward integration, and entering new markets rather than capital investment in new facilities.
- No new building blocks or capacity additions are planned currently.
Track SMS Pharmaceuticals — get its next earnings analysis in your feed
How does SMS Pharmaceuticals rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does SMS Pharmaceuticals rank in Pharmaceuticals & Biotechnology?
Compare SMS Pharmaceuticals against every Pharmaceuticals & Biotechnology company (Q2 FY23) on revenue, margins and earnings-call signals.
Continue your research
What SMS Pharmaceuticals's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem